Skip to main content
NTv Online

World

World
  • Africa
  • Americas
  • Asia Pacific
  • Europe
  • Mid East
  • More
  • Offbeat
  • South & Central Asia
  • Viral
  • Bangla Version
  • Archive
  • Bangladesh
  • World
  • Sports
  • Entertainment
  • Business
  • Comment
  • Education
  • Life
  • Health
  • Art & Culture
  • Election
  • বাংলা
  • Bangladesh
  • World
  • Sports
  • Entertainment
  • Business
  • Comment
  • Education
  • Life
  • Health
  • Art & Culture
  • Election
  • বাংলা
  • Bangla Version
  • Archive
Follow
  • World
Reuters
04 February, 2021, 15:50
Update: 04 February, 2021, 15:53
More News
Mosaddak Ali, two others discharged in money laundering case
Over 1000 people killed, 400 lost eyesight in student movement: Health Adviser
Dhaka International Mobile Film Festival's Closing Ceremony
Mastermind’s finance event to knock the city
Metro rail now open for public

World faces around 4,000 COVID-19 variants as researchers explore mixed vaccine shots

Reuters
04 February, 2021, 15:50
Update: 04 February, 2021, 15:53

The world faces around 4,000 variants of the virus that causes COVID-19, prompting a race to improve vaccines, Britain said on Thursday, as researchers began to explore mixing doses of the Pfizer and AstraZeneca shots.

Thousands of variants have been documented as the virus mutates, including the so-called British, South African and Brazilian variants which appear to spread more swiftly than others.

British Vaccine Deployment Minister Nadhim Zahawi said it was very unlikely that the current vaccines would not work against the new variants.

“Its very unlikely that the current vaccine won’t be effective on the variants whether in Kent or other variants especially when it comes to severe illness and hospitalisation,” Zahawi told Sky News.

“All manufacturers, Pfizer-BioNTech, Moderna, Oxford-AstraZeneca and others, are looking at how they can improve their vaccine to make sure that we are ready for any variant - there are about 4,000 variants around the world of COVID now.”

While thousands of variants have arisen as the virus mutates on replication, only a very small minority are likely to be important and to change the virus in an appreciable way, according to the British Medical Journal.

The so called British variant, known as VUI-202012/01, has mutations including a change in the spike protein that viruses use to bind to the human ACE2 receptor - meaning that it is probably easier to catch.

“We have the largest genome sequencing industry - we have about 50% of the world’s genome sequencing industry - and we are keeping a library of all the variants so that we are ready to respond - whether in the autumn or beyond - to any challenge that the virus may present and produce the next vaccine,” Zahawi said.

VACCINE RACE

The novel coronavirus - known as SARS-CoV-2 - has killed 2.268 million people worldwide since it emerged in China in late 2019, according to Johns Hopkins University of Medicine.

Israel is currently far ahead of the rest of the world on vaccinations per head of population, followed by the United Arab Emirates, the United Kingdom, Bahrain, the United States and then Spain, Italy and Germany.

Britain on Thursday launched a trial to assess the immune responses generated if doses of the vaccines from Pfizer and AstraZeneca are combined in a two-shot schedule.

The British researchers behind the trial said data on vaccinating people with the two different types of vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world. Initial data on immune responses is expected to be generated around June.

The trial will examine the immune responses of an initial dose of Pfizer vaccine followed by a booster of AstraZeneca’s, as well as vice versa, with intervals of four and 12 weeks.

Both the mRNA shot developed by Pfizer and BioNtech and the adenovirus viral vector vaccine developed by Oxford University and AstraZeneca are currently being rolled out in Britain, with a 12-week gap between two doses of the same vaccine.

Most Read
  1. WHO site shows how they refuse to acknowledge scientific evidence on vaping
  2. Tholos Foundation urges Bangladesh govt not to ban e-cigarettes
  3. India bans service charge at hotels and restaurants
  4. Bangladesh and Australia working towards key trade partners
  5. Bigger and better Mother Language Day Walk
  6. Islamic State loses second leader in two years
Most Read
  1. WHO site shows how they refuse to acknowledge scientific evidence on vaping
  2. Tholos Foundation urges Bangladesh govt not to ban e-cigarettes
  3. India bans service charge at hotels and restaurants
  4. Bangladesh and Australia working towards key trade partners
  5. Bigger and better Mother Language Day Walk
  6. Islamic State loses second leader in two years

Follow Us

Alhaj Mohammad Mosaddak Ali

Chairman & Managing Director

NTV Online, BSEC Building (Level-8), 102 Kazi Nazrul Islam Avenue, Karwan Bazar, Dhaka-1215 Telephone: +880255012281 up to 5, Fax: +880255012286 up to 7

Browse by Category

  • About NTV
  • NTV Programmes
  • Advertisement
  • Web Mail
  • NTV FTV
  • Satellite Downlink
  • Europe Subscription
  • USA Subscription
  • Privacy Policy
  • Terms & Conditions
  • Contact

Our Newsletter

To stay on top of the ever-changing world of business, subscribe now to our newsletters.

* We hate spam as much as you do

Alhaj Mohammad Mosaddak Ali

Chairman & Managing Director

NTV Online, BSEC Building (Level-8), 102 Kazi Nazrul Islam Avenue, Karwan Bazar, Dhaka-1215 Telephone: +880255012281 up to 5, Fax: +880255012286 up to 7

Reproduction of any content, news or article published on this website is strictly prohibited. All rights reserved